E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
patients with cervico-facial neoplasms receiving concomitant chemoradiotherapy. |
pazienti con neoplasie del distretto cervico-faciale sottoposti a trattamento chemioradioterapico concomitante. |
|
E.1.1.1 | Medical condition in easily understood language |
patients with cervical tumor treated with chemoradiotherapy |
pazienti con tumore cervico faciale sottoposti a trattamento chemioradioterapico |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10029104 |
E.1.2 | Term | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The aim of the study is to test the efficacy of rinsings with dexamethasone versus rinsing with benzydamine in reducing the incidence of oral mucositis in patients with cervico-facial neoplasms receiving concomitant chemoradiotherapy. |
Obiettivo dello studio è testare l'efficacia degli sciacqui con desametasone versus sciacqui con benzidamina nel ridurre l'incidenza della mucosite del cavo orale in pazienti con neoplasie del distretto cervico-faciale sottoposti a trattamento chemioradioterapico concomitante. |
|
E.2.2 | Secondary objectives of the trial |
432/5000 • Need to resort to opioid analgesics during treatment (in morphine equivalents); • Resolution resolution of grade 3 and 4 mucositis at grade <1; • Incidence of mycoses of grade 3 or 4 oral cavity according to the CTCAE 4.03 criteria during treatment; • Weight maintenance throughout the duration of treatment; • Evaluation of the Quality of Life by completing the validated EORTC QLQ-C30 questionnaire. |
• Necessità di ricorso ad analgesici oppioidi durante il trattamento (in equivalenti di morfina); • Tempo di risoluzione della mucosite di grado 3 e 4 a grado < 1; • Incidenza di micosi del cavo orale di grado 3 o 4 secondo i criteri CTCAE 4.03 durante il trattamento; • Mantenimento di peso durante tutta la durata del trattamento; • Valutazione della Quality of Life mediante compilazione del questionario validato EORTC QLQ-C30. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Age over 18 years;
• Histological diagnosis of cervico-facial cancer; • Clinical stage III or IV with indication of concomitant chemoradiotherapy with cisplatin (exclusive or post-surgery adjuvant); • Performance status 0-2 according to ECOG;
• Adequate medullary crasis (hemoglobin> 10.0 g / dL, leukocytes> 3000 / µL, neutrophils> 1500 / µL, platelets > 100,000 / ul);
• Proper renal and hepatic function;
• Written informed consent according to the procedures of local Ethics Committees. |
• Età superiore a 18 anni;
• Diagnosi istologica di tumore del distretto cervico- faciale; • Stadio clinico III o IV con indicazione a trattamento chemioradioterapico concomitante con cisplatino (esclusivo o adiuvante post-chirurgia); • Performance status 0-2 secondo ECOG;
• Crasi midollare adeguata (emoglobina > 10.0 g/dL, leucociti > 3000/µL, neutrofili >1500/µL, piastrine >100.000/µL);
• Funzione renale ed epatica adeguata;
• Consenso informato scritto secondo le procedure dei Comitati Etici locali. |
|
E.4 | Principal exclusion criteria |
• Presence of distant metastases
• Previous radiotherapy treatment and / or chemotherapy; • Uncontrolled internal pathology;
• Other anticancer therapies in progress;
• Active immunological diseases;
• Concomitant immunosuppressive therapy;
• Presence of mucositis of the already active oral cavity. |
• Presenza di metastasi a distanza
• Precedente trattamento radioterapico e/o chemioterapico; • Patologia internistica non controllata;
• Altre terapie antitumorali in corso;
• Malattie immunologiche attive;
• Concomitante terapia immunosoppressiva;
• Presenza di mucosite del cavo orale già attiva. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Reduction in the incidence of oral mucositis in the oral cavity> 2 in the 12 weeks following the beginning of the chemoradiotherapy treatment, according to the CTCAE criteria 4.03 |
Riduzione dell’incidenza della mucosite del cavo orale di grado > 2 nelle 12 settimane successive all’inizio trattamento chemioradioterapico, secondo i criteri CTCAE 4.03 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 24 |
E.8.9.1 | In the Member State concerned days | 73 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 24 |
E.8.9.2 | In all countries concerned by the trial days | 73 |